Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advagraf-based steroid minimization after kidney transplantation and risk of new-onset diabetes
NL-OMON38176Phase 4Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Apr 2011
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tacrolimus, corticosteroids in kidney transplant, end-stage kidney disease (ESKD), sponsored by Astellas Pharma. Started Apr 2011; status: active, not recruiting.
02
Drugs
tacrolimuscorticosteroids
03
Conditions
kidney transplantend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NL-OMON38176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38176.